[vc_row type=”vc_default” full_width_row=”true” bg_type=”bg_color” bg_override=”full” bg_color_value=”#f4f4f4″ css=”.vc_custom_1491338473651{margin-top: -70px !important;}”][vc_column][vc_custom_heading text=”PARTNER CUN” font_container=”tag:h1|text_align:left|color:%23232323″ use_theme_fonts=”yes”][vc_custom_heading text=”P.I. BRUNO SANGRO” font_container=”tag:h2|text_align:left|color:%23606060″ use_theme_fonts=”yes”][vc_custom_heading text=”CLINICA UNIVESIDAD DE NAVARRA” font_container=”tag:h4|text_align:left|color:%238e8e8e” use_theme_fonts=”yes”][/vc_column][/vc_row][vc_row][vc_column width=”1/6″][vc_empty_space height=”15px”][vc_single_image image=”145″ img_size=”full” onclick=”custom_link” img_link_target=”_blank” image_hovers=”false” link=”https://www.unav.edu/”][/vc_column][vc_column width=”2/3″][vc_column_text]

Clínica Universidad de Navarra is a tertiary care hospital in Northern Span. The Liver Unit has an extensive experience in therapeutic innovation in hepatocellular carcinoma (HCC). In collaboration with the Department of Immunology and Immunotherapy has led national and international clinical trials that support the use of immune checkpoint inhibitors for the treatment of this tumor.

Bruno Sangro MD heads the Liver Unit at Clínica Universidad de Navarra and is Professor of Medicine at the School of Medicine. He has been principal investigator for several clinical trials on immunotherapy of HCC. Pablo Sarobe PhD has a long-standing experience in immunology of liver disease including liver cancer. Mercedes Iñarrairaegui MD is Consultant at the Liver Unit and has a strong focus on translational and clinical research in liver cancer. The group will collaborate in patient recruitment, clinical analysis and immune validation in animal models.

[/vc_column_text][/vc_column][vc_column width=”1/6″][vc_single_image image=”253″ img_size=”full” alignment=”center” image_hovers=”false”][/vc_column][/vc_row][vc_row][vc_column]


1) Prieto J, Melero I, Sangro B. Immunological landscape and immunotherapy of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2015 Dec;12(12):681-700.

2) Morales-Kastresana A, et al., Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model. Clin Cancer Res. 2013 Nov 15;19 (22):6151-62.

3) Sangro B, et al., A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol. 2013 Jul;59 (1):81-8.

4) Gil-Alzugaray B, et al., Prognostic factors and prevention of radioembolization-induced liver disease. Hepatology. 2013 Mar;57 (3):1078-87.

5) Sangro B, et al., Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology. 2011 Sep 2;54(3):868-78.